During the year 1956 there appeared in the ophthalmic literature two reports concerned with toxic effects produced upon the retina by a new drug belonging to the group of so-called tranquilizers (Verrey,1 Goar and Fletcher2). The new drug, 3-chloro-10- [2-N-(methylpiperidyl)ethyl] phenothiazine, designated by its producer, Sandoz Pharmaceutical, as NP 207, was developed in an effort to reduce the systemic effects of chlorpromazine hydrochloride. This goal was, indeed, achieved, and the tranquilizing effect of NP 207 proved to be as good as, or better than, that of chlorpromazine, from which it was derived. However, it soon appeared that NP 207 caused very undesirable visual disturbances. Subjectively they expressed themselves in a more or less severe impairment of dark adaptation and in a loss of visual acuity. Objectively one found in the early stages a hyperemia of the disc and some edema of the retina and in the later
BURIAN HM, FLETCHER MC. Visual Functions in Patients with Retinal Pigmentary Degeneration Following the Use of NP 207. AMA Arch Ophthalmol. 1958;60(4):612–629. doi:10.1001/archopht.1958.00940080632009
Ophthalmology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.